Celik, I. Et Al. 2021. Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.75, no.12 .

Celik, I., Eryilmaz-Eren, E., Kilinc-Toker, A., Eren, D., Yildiz, M., Kanat, A., ... Topaloglu, U. S.(2021). Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.75, no.12.

Celik, Ilhami Et Al. "Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia," INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.75, no.12, 2021

Celik, Ilhami Et Al. "Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia." INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.75, no.12, 2021

Celik, I. Et Al. (2021) . "Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia." INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.75, no.12.

@article{article, author={Ilhami Celik Et Al. }, title={Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia}, journal={INTERNATIONAL JOURNAL OF CLINICAL PRACTICE}, year=2021}